Last kr72.90 SEK
Change Today +0.20 / 0.28%
Volume 2.9M
EKTAB On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
OTC US
Frankfurt
As of 11:30 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAB) Snapshot

Open
kr72.85
Previous Close
kr72.70
Day High
kr73.75
Day Low
kr72.35
52 Week High
09/23/13 - kr107.93
52 Week Low
09/18/14 - kr71.65
Market Cap
27.9B
Average Volume 10 Days
2.3M
EPS TTM
kr2.66
Shares Outstanding
368.6M
EX-Date
08/29/14
P/E TM
27.4x
Dividend
kr1.50
Dividend Yield
2.74%
Current Stock Chart for ELEKTA AB-B SHS (EKTAB)

Related News

No related news articles were found.

elekta ab-b shs (EKTAB) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAB) Details

Elekta AB (publ), develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend sytem for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualize tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,750 Employees
Last Reported Date: 08/28/14
Founded in 1972

elekta ab-b shs (EKTAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAB) Key Developments

Elekta AB Appoints Helene Vibbleus as New Chief Audit Executive and Caroline Mofors as Group Compliance Officer

Elekta has appointed Helene Vibbleus as new Chief Audit Executive and Caroline Mofors as Group Compliance Officer. Through both of these recruitments, Elekta continues to develop its internal audit and compliance functions, while strengthening the Group's capacity for risk management and internal control. Helene and Caroline will report their observations and actions directly to the Board and Audit Committee. Helene Vibbleus has previously worked at Electrolux, as head of the internal audit function and on PwC as auditor and partner. Caroline Mofors comes to Elekta from Ericsson, where she worked with Compliance and legal issues.

Elekta's Versa HD Radiation Therapy System Now Available for Treatment of Cancer Patients in Japan

Elekta announced that cancer care providers in Japan have the opportunity to strengthen their cancer treatment capacity with the recent clearance of Elekta's Versa HD(TM) by Japan's Ministry of Health, Labor and Welfare. Versa HD is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body. In a single system, Versa HD is capable of delivering conventional therapies for a wide range of indications commonly seen in the clinic, while also permitting treatment of complex cancers that require exceptional targeting accuracy. The clearance of Versa HD in Japan follows CE marking of the system from the European Union and 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2013.

Elekta AB Approves Ordinary and Extraordinary Dividend, Payable on September 5, 2014

Elekta AB approved dividend of SEK 2.00, of which SEK 1.50 is an ordinary dividend and SEK 0.50 is an extraordinary dividend, to be distributed to shareholders. The remaining amount is to be carried forward. The record date for the dividend was set at September 2, 2014 and the payment is expected to be made on September 5, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAB:SS kr72.90 SEK +0.20

EKTAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $7.95 USD -0.15
American Shared Hospital Services $2.24 USD +0.09
IsoRay Inc $2.17 USD -0.11
MRI Interventions Inc $1.19 USD +0.04
RaySearch Laboratories AB kr43.00 SEK 0.00
View Industry Companies
 

Industry Analysis

EKTAB

Industry Average

Valuation EKTAB Industry Range
Price/Earnings 26.5x
Price/Sales 2.5x
Price/Book 4.2x
Price/Cash Flow 25.6x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.